Insider Buying: Harrow Health, Inc. (NASDAQ:HROW) Major Shareholder Purchases 50,000 Shares of Stock

Harrow Health, Inc. (NASDAQ:HROWGet Free Report) major shareholder Opaleye Management Inc. purchased 50,000 shares of the firm’s stock in a transaction on Thursday, March 28th. The shares were acquired at an average price of $12.82 per share, with a total value of $641,000.00. Following the completion of the acquisition, the insider now owns 3,745,600 shares in the company, valued at approximately $48,018,592. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this link. Large shareholders that own at least 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

Opaleye Management Inc. also recently made the following trade(s):

  • On Wednesday, March 20th, Opaleye Management Inc. purchased 50,600 shares of Harrow Health stock. The shares were acquired at an average price of $9.65 per share, with a total value of $488,290.00.

Harrow Health Stock Performance

Shares of HROW opened at $13.23 on Friday. The company has a debt-to-equity ratio of 2.60, a current ratio of 2.83 and a quick ratio of 2.61. The stock has a 50-day moving average of $10.80 and a 200-day moving average of $11.58. The company has a market cap of $467.81 million, a PE ratio of -17.64 and a beta of 0.45. Harrow Health, Inc. has a one year low of $7.60 and a one year high of $28.25.

Analyst Upgrades and Downgrades

Several brokerages have recently commented on HROW. TheStreet downgraded Harrow Health from a “c-” rating to a “d+” rating in a research note on Tuesday, December 12th. B. Riley reduced their target price on Harrow Health from $30.00 to $26.00 and set a “buy” rating for the company in a research note on Friday, March 22nd.

Read Our Latest Analysis on HROW

Institutional Trading of Harrow Health

Large investors have recently made changes to their positions in the company. Kennedy Capital Management LLC acquired a new position in Harrow Health during the 3rd quarter valued at about $1,750,000. Jump Financial LLC acquired a new position in Harrow Health during the 3rd quarter valued at about $1,038,000. Stifel Financial Corp acquired a new position in Harrow Health during the 3rd quarter valued at about $4,887,000. Braidwell LP boosted its stake in Harrow Health by 24.5% during the 3rd quarter. Braidwell LP now owns 1,808,684 shares of the company’s stock valued at $25,991,000 after purchasing an additional 356,146 shares during the last quarter. Finally, Rice Hall James & Associates LLC acquired a new position in Harrow Health during the 3rd quarter valued at about $3,598,000. 72.76% of the stock is currently owned by institutional investors and hedge funds.

Harrow Health Company Profile

(Get Free Report)

Harrow Health, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company also holds equity interests in Surface Ophthalmics, Inc, a clinical-stage pharmaceutical company that focuses on the development and commercialization of therapeutics for ocular surface diseases; Melt Pharmaceuticals, Inc, a clinical-stage pharmaceutical company that focused on the development and commercialization of proprietary non-intravenous, sedation, and anesthesia therapeutics for human medical procedures in hospital, outpatient, and in-office settings; and Eton Pharmaceuticals, Inc, a commercial-stage pharmaceutical company that engages in developing and commercializing drug products.

Featured Articles

Receive News & Ratings for Harrow Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Harrow Health and related companies with MarketBeat.com's FREE daily email newsletter.